Diagnostic use of snake venom components in the coagulation laboratory

Toxins and Hemostasis: From Bench to Bedside

Volumn , Issue , 2011, Pages 747-766

  Perchuc, Anna Maria ^a,b   Wilmer, Marianne ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c Roche Diagnostics Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960622739     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-9295-3_43     Document Type: Chapter

References (109)

1. Andrews, R.K., Kamiguti, A.S., Berlanga, O., Leduc, M., Theakston, R.D., Watson, S.P., 2001. The use of snake venom toxins as tools to study platelet receptors for collagen and von Willebrand factor. Haemostasis 31, 155-172.
2. Baidoo, K.E., Knight, L.C., Lin, K.S., Gabriel, J.L., Romano, J.E., 2004. Design and synthesis of a short-chain bitistatin analogue for imaging thrombi and emboli. Bioconjug. Chem. 15, 1068-1075.
3. Bachmann, F., Duckert, F., Koller, F., 1958. The Stuart-Prower assay and its clinical significance. Thromb. Diath. Haemorrh. 2, 24-38.
4. Braud, S., Bon, C., Wisner, A., 2000. Snake venom proteins acting on hemostasis. Biochimie 82, 851-859.
5. Brinkhous, K.M., Read, M.S., Fricke, W.A., Wagner, R.H., 1983. Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex. Proc. Natl. Acad. Sci. U.S.A. 80, 1463-1466.
6. Brinkhous, K.M., Smith, S.V., Read, M.S., 1988. Botrocetin and von Willebrand factor, in: Pirkle, H., Markland, F.S., Jr. (Eds.), Hemostasis and Animal Venoms. Marcel Dekker Inc., New York, pp. 377-398.
7. Calatzis, A., Peetz, D., Haas, S., Spannagl, M., Rudin, K., Wilmer, M., 2008. Prothrombinaseinduced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am. J. Clin. Pathol. 130, 446-454.
8. Canoso, R.T., Hutton, R.A., Deykin, D., 1979. The haemostatic defect of chronic liver disease. Gastroenterology 76, 540-547.
9. Carr, M.E., Carr, S.L., Greilich, P.E., 1996. Heparin ablates force development during platelet mediated clot retraction. Thromb. Haemost. 75, 674-678.
10. Castro, H.C., Zingali, R.B., Albuquerque, M.G., Pujol-Luz, M., Rodrigues, C.R., 2004. Snake venom thrombin-like enzymes: From reptilase to now. Cell Mol. Life Sci. 61, 843-856.
11. Chattopadhyay, A., Fair, D.S., 1989. Molecular recognition in the activation of human blood coagulation factor X. J. Biol. Chem. 264, 11035-11043.
12. Clemetson, K.J., Navdaev, A., Dörmann, D., Du, X.Y., Clemetson, J.M., 2001. Multifunctional snake C-type lectins affecting platelets. Haemostasis 31, 148-154.
13. Collados, M.T., Fernandez, J., Paramo, J.A., Montes, R., Borbolla, J.R., Montano, L.F., Rocha, E., 1997. Purification and characterization of a variant of human prothrombin: prothrombin Segovia. Thromb. Res. 85, 465-477.
14. Court, E.L., 1997. Lupus anticoagulants: pathogenesis and laboratory diagnosis. Br. J. Biomed. Sci. 54, 287-298.
15. Cunningham, M.T., Brandt, J.T., Laposata, M., Olson, J.D., 2002. Laboratory diagnosis of dysfibrinogenaemia. Arch. Pathol. Lab. Med. 126, 499-505.
16. Denson, K.W.E., 1961. The specific assay of Prower Stuart factor and factor VII. Acta. Haematol. 25, 105-120.
17. Favaloro, E.J., Soltani, S., McDonald, J., Grezchnik, E., Easton, L., 2006. Activated protein C resistance: The influence of ABO-blood group, gender and age. Thromb. Res. 117, 665-670.
18. Fukushima, S., Tanaka, T., Sato, T., Shirakawa, Y., Asayama, K., Shirahata, A., 2002. Prothrombin levels in newborn infants by the carinactivase-1 method. Semin. Thromb. Hemost. 28, 539-544.
19. Funk, C., Gmur, J., Herold, R., Straub, P.W., 1971. Reptilase-R, a new reagent in blood coagulation. Br. J. Haematol. 21, 43-52.
20. Gempeler-Messina, Volz K., Bühler, B., Müller, C., 2001. Protein C activators from snake venoms and their diagnostic use, in: Bon, C., Kini, M., Markland, F.S., Marsh, N.A., Rosing, J. (Eds.), International Conference on Exogenous Factors Affecting Thrombosis and Haemostasis. Haemostasis 31, S. Karger Medical and Scientific Publishers, pp. 266-272.
21. Gerads, I., Tans, G., Yukelson, L.Ya, Zwaal, R.F., Rosing, J., 1992. Activation of bovine factor V by an activator purified from the venom of Naja naja oxiana. Toxicon 30, 1065-1079.
22. Gowda, D.C., Jackson, C.M., Hensley, P., Davidson, E.A., 1994. Factor X-activating glycoprotein of Russell's viper venom. Polypeptide composition and characterization of the carbohydrate moieties. J. Biol. Chem. 269, 10644-10650.
23. Graff, J., Picard-Willems, B., Harder, S., 2007. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int. J. Clin. Pharmacol. Ther. 45, 237-243.
24. Harder, S., Parisius, J., Picard-Willems, B., 2008. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 123, 396-403.
25. Hardisty, R.M., Hutton, R.A., 1966. Platelet aggregation and the availability of platelet factor 3. Br. J. Haematol. 12, 764-776.
26. Harenberg, J., Giese, C., Hagedorn, A., Traeger, I., Fenyvesi, T., 2007. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost. 33, 503-507.
27. Harenberg, J., Jörg, I., Vukojevic, Y., Mikus, G., Weiss, C., 2008. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur. J. Clin. Pharmacol. 64, 555-563.
28. Hoagland, L.E., Triplett, D.A., Peng, F., Barna, L., 1996. APC-resistance as measured by a textarin time assay-comparison to the APTT-based method. Thromb. Res. 83, 363-373.
29. Howie, P.W., Prentice, C.R.M., McNicol, G.P., 1973. A method of antithrombin estimation using plasma defibrinated with ancrod. Br. J. Haematol. 25, 101-110.
30. Hutton, R.A., Warrell, D.A., 1993. Action of snake venom components on the haemostatic system. Blood Rev. 7, 176-189.
31. Inoue, K., Morita, T., 1993. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X. Eur. J. Biochem. 218, 153-163. (Leipzig) 115, 483-487.
32. Jy, W.C., Horstman, L.L., Wang, F., Duncan, R.C., Ahn, Y.S., 1995. Platelet factor 3 in plasma fractions-its relation to micro-particle size and thromboses. Thromb. Res. 80, 471-482.
33. Kamiguti, A.S., 2005. Platelets as targets of snake venom metalloproteinases. Toxicon 45, 1041- 1049.
34. Kathiresan, S., Shiomura, J., Jang, I.K., 2002. Argatroban. J. Thromb. Thrombolysis 13, 41-47.
35. Kaufmann, R., Zieger, M., Tausch, S., Henklein, P., Nowak, G., 2000. Meizothrombin, an intermediate of prothrombin activation, stimulates human glioblastoma cells by interaction with PAR-1-type thrombin receptors. J. Neurosci. Res. 59, 643-648.
36. Keller, F.G., Ortel, T.L., Quinn-Allen, M.A., Kane, W.H., 1995. Thrombin-catalysed activation of recombinant human factor V. Biochemistry 34, 4118-4124.
37. Kini, R.M., 2005. The intriguing world of prothrombin activators from snake venom. Toxicon 45, 1133-1145.
38. Kini, R.M., 2006, Anticoagulant proteins from snake venoms: structure, function and mechanism. Biochem. J. 397, 377-387.
39. Kini, R.M., Rao, V.S., Joseph, J.S., 2001. Procoagulant proteins from snake venoms, in: Bon, C., Kini, M., Markland, F.S., Marsh, N.A., Rosing, J. (Eds.), International Conference on Exogenous Factors Affecting Thrombosis and Haemostasis. Haemostasis 31, S. Karger Medical and Scientific Publishers, pp. 218-224.
40. Kini, R.M., Joseph, J.S., Rao, V.S., 2002. Prothrombin activators from snake venoms, in: Menez, A. (Ed.), Perspectives in Molecular Toxinology. John Wiley & Sons Ltd., Chichester, pp. 341-355.
41. Kisiel, W., Canfield, W.M., 1981. Snake venom proteases that activate blood coagulation factor V, in: Lorand, L. (Ed.), Methods in Enzymology (vol. 80). Academic Press, New York, pp. 275-285.
42. Klein, J.D., Walker, F.D., 1986. Purification of a Protein C activator from the venom of the Southern copperhead snake (Agkistrodon contortrix contortrix). Biochemistry 25, 4175-4178.
43. Knight, L.C., Romano, J.E., 2005. Functional expression of bitistatin, a disintegrin with potential use in molecular imaging of thromboembolic disease. Protein Expr. Purif. 39, 307-319.
44. Koh, D.C., Armugam, A., Jeyaseelan, K., 2006. Snake venom components and their applications in biomedicine. Cell Mol. Life Sci. 63, 3030-3041.
45. Kornalik, F., 1985. The influence of snake venom enzymes on blood coagulation. Pharmacol. Ther. 29, 353-405.
46. Kornalik, F., 1990. Toxins affecting blood coagulation and fibrinolysis, in: Shier, W.T., Mebs, D. (Eds.), Handbook of Toxicology. Marcel Dekker Inc., New York, pp. 683-760.
47. Kornalik, F., Vorlova, Z., 1988. Ecarin test in diagnosis of dicoumarol therapy, liver diseases and DIC. Folia Haematol. (Leipzig) 115, 483-487.
48. Kumar, R., Beguin, S., Hemker, H.C., 1994. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb. Haemost. 72, 713-721.
49. Lange, U., Nowak, G., Bucha, E., 2003. Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol. Haemost. Thromb. 33, 184-191.
50. Latallo, Z., Teisseyre, E., 1971. Evaluation of reptilase-R and thrombin clotting time in the presence of fibrinogen degradation products and heparin. Scand. J. Haematol. 1971; 261-266.
51. Lu, Q., Clemetson, J.M., Clemetson, K.J., 2005. Snake venoms and hemostasis. J. Thromb. Haemost. 3, 1791-1799.
52. Markland, F.S. Jr., 1997. Snake venoms. Drugs 54(Suppl 3), 1-10.
53. Markland, F.S., 1998. Snake venoms and the hemostatic system. Toxicon 36, 1749-1800.
54. Marsh, N.A., 1994. Snake venoms affecting the haemostatic mechanism-a consideration of their mechanisms, practical applications and biological significance. Blood Coagul. Fibrinolysis 5, 399-410.
55. Marsh, N., 2001. Diagnostic uses of snake venom, in: Bon, C., Kini, M., Markland, F.S., Marsh, N.A., Rosing, J. (Eds.), International Conference on Exogenous Factors Affecting Thrombosis and Haemostasis. Haemostasis 31, S. Karger Medical and Scientific Publishers, pp. 211-217.
56. Marsh, N.A., Fyffe, T.L., 1996. Practical applications of snake venom toxins in haemostasis. Boll. Soc. Ital., Biol. Sper. 72, 263-278.
57. Marsh, N., Williams, V., 2005. Practical applications of snake venom toxins in haemostasis. Toxicon 45, 1171-1181.
58. Matsui, T., Fujimura, Y., Titani, K., 2000. Snake venom proteases affecting hemostasis and thrombosis. Biochim. Biophys. Acta 1477, 146-156.
59. Matsui, T., Hamako, J., 2005. Structure and function of snake venom toxins interacting with human von Willebrand factor. Toxicon 45, 1075-1087.
60. Meier, J., Stocker, K., 1991. Snake venom protein C activators, in: Tu, A.T. (Ed.), Handbook of Natural Toxins. Marcel Dekker Inc., New York-Basel-Hong Kong, pp. 265-280.
61. Meier, J., 1998. Proteinases activating protein C, in: Bailey, G.S. (Ed.), Enzymes from Snake Venom. Alaken Inc., Fort Collins, CO, pp. 253-285.
62. Miura, S., Nishida, S., Makita, K., Sakurai, Y., Shimoyama, T., Sugimoto, M., Yoshioka, A., Ishii, K., Kito, M., Kobayashi, T., Fujimura, Y., 1996. Inhibition assay for the binding of biotinylated von Willebrand factor to platelet-bound microtiter wells in the presence of ristocetin or botrocetin. Anal., Biochem. 236, 215-220.
63. Moore, G.W., 2007. Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb. J. 5, 12-16.
64. Moore, G.W., Savidge, G.F., 2004. Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants. Blood Coagul. Fibrinolysis 15, 279-82.
65. Moore, G.W., Smith, M.P., Savidge, G.F., 2003. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinised patients with lupus anticoagulants. Blood Coagul. Fibrinolysis 14, 307-312.
66. Morita, T., 1998. Proteases which activate factor X, in: Bailey, G.S. (Ed.), Enzymes from Snake Venom. Alaken Inc., Fort Collins, CO, pp. 179-208.
67. Moser, M., Ruef, J., Peter, K., Kohler, B., Gulba, D.C., Paterna, N., Nordt, T., Kubler, W., Bode, C., 2001. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J. Thromb. Thrombolysis 12, 165-169.
68. Nowak, G., 2003/2004. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol. Haemost. Thromb. 33, 173-183.
69. Nowak, G., Bucha, E., 1996. Quantitative determination of hirudin in blood and body fluids. Semin. Thromb. Hemost. 22, 197-202.
70. Novoa, E., Seegers, W.H., 1980. Mechanisms of α-thrombin and β- Thrombin-E formation: use of ecarin for isolation of meizothrombin 1. Thromb. Res. 18, 657-668.
71. Parmar, K., Lefkou, E., Doughty, H., Connor, P., Hunt, B.J., 2009. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagul. Fibrinolysis 20, 271-275.
72. St. Pierre, L., Masci, P.P., Filippovich, I., Sorokina, N., Marsh, N., Miller, D.J., Lavin, M.F., 2005. Comparative analysis of prothrombin activators from the venom of Australian elapids. Mol. Biol. Evol. 22, 1853-1864.
73. Pirkle, H., 1998. Thrombin-like enzymes from snake venoms: An updated inventory. Scientific and standardization committee's registry of exogenous hemostatic factors. Thromb. Haemost. 79, 675-683.
74. Quehenberger, P., Handler, S., Mannhalter, C., Pabinger-Fasching, I., Speiser, W., 2000. Evaluation of a highly specific functional test for the detection of factor V Leiden. Int. J. Clin. Lab. Res. 30, 113-117.
75. Quick, A.J., 1971. Thromboplastin generation: effect of the Bell-Alton reagent and Russell's viper venom on prothrombin consumption. Am. J. Clin. Pathol. 55, 555-560.
76. Rabinowitz, I., Tuley, E.A., Mancuso, D.J., Randi, A.M., Firkin, B.G., Howard, M., Sadler, J.E., 1992. Von Willebrand disease type B: A missense mutation selectively abolishes ristocetininduced vonWillebrand factor binding to platelet glycoprotein Ib. Proc. Natl. Acad. Sci. U.S.A. 89, 9846-9849.
77. Ranby, M., Norrman, B., Wallen, P., 1982. A sensitive assay for tissue plasminogen activator. Thromb. Res. 27, 743-749.
78. Read, M.S., Smith, S.V., Lamb, M.A., Brinkhous, K.M., 1989. Role of botrocetin in platelet agglutination: Formation of an activated complex of botrocetin and von Willebrand factor. Blood 74, 1031-1035.
79. Robert, A., Eschwege, V., Hameg, H., Drouet, L., Aillaud, M.F., 1996. Anticoagulant response to Agkistrodon contortrix venom (ACVtest): A new global test to screen for defects in the anticoagulant protein C pathway. Thromb. Haemost. 75, 562-566.
80. Rooney, A.M., McNally, T., Mackie, I.J., Machin, S.J., 1994. The taipan snake venom time: A new test for lupus anticoagulant. J. Clin. Pathol. 47, 497-501.
81. Rosing, J., Govers-Riemslag, J.W.P., Yukelson, L., Tans, G., 2001. Factor V activation and inactivation by venom proteases, in: Bon, C., Kini, M., Markland, F.S., Marsh, N.A., Rosing, J. (Eds.), International Conference on Exogenous Factors Affecting Thrombosis and Haemostasis. Haemostasis 31, S. Karger Medical and Scientific Publishers, pp. 241-246.
82. Rosing, J., Tans, G., 1988. Meizothrombin, a major product of factor Xa-catalysed prothrombin activation. Thromb. Haemost. 60, 355-360.
83. Rosing, J., Tans, G., 1992. Structural and functional properties of snake venom prothrombin activators. Toxicon 30, 1515-1527.
84. Sakuragawa, N., Takahashi, K., Hoshiyama, M., Jimbo, C., Matsuoka, M., Onishi, Y., 1975. Significance of a prothrombin assay method using Echis carinatus venom for diagnostic information in disseminated intravascular coagulation syndrome. Thromb. Res. 7, 643-653.
85. Sarig, G., Aberbach, I., Schliamser, L., Blumenfeld, Z., Brenner, B., 2006. Evaluation of ProC Global assay in women with a history of venous thromboembolism on hormonal therapy. Thromb. Haemost. 96, 578-583.
86. Schöni, R. 2005. The use of snake venom-derived compounds for new functional diagnostic test kits in the field of haemostasis, in: Kini, R.M., Marsh, N., Markland, F.S., Broady, K.W. (Eds.), Proceedings of the Third International Conference, EFATH 2005. Pathophysiol. Haemost. Thromb. 34, S. Karger Medical and Scientific Publishers, pp. 234-240.
87. Sillero, P.L., Fernández de Velasco, J., Loscertales, J., Espinoza, J., Soto, C., Tomás, J.F., 2001. ProC global: An automated screening test for factor V Leiden and prothrombin mutation 20210 G to A detection. Thromb. Res. 101, 215-216.
88. Stevens, W.K., Cote, H.C.F., MacGillivray, R.T.A., Nesheim, M.E., 1996. Calcium ion modulation of meizothrombin autolysis at Arg55-Asp56 and catalytic activity. J. Biol. Chem. 271, 8062- 8067.
89. Stocker, K., 1986. Use of snake venom proteins in the diagnosis and therapy of haemostatic disorders, in: Kornalik, K., Mebs, D. (Eds.), 7th European Symposium on Animal, Plant and Microbial Toxins. Prague, pp. 9-40.
90. Stocker, K., 1998. Research, diagnostic and medicinal uses of snake venom enzymes, in: Bailey, G.S. (Ed.), Enzymes from Snake Venom. Alaken Inc., Fort Collins, CO, pp. 705-736.
91. Stocker, K., Fischer, H., Meier, J., Brogli, M., Svendsen, L., 1986. Protein C activators in snake venoms. Behring Inst. Mitt. 79, 37-47.
92. Stocker, K., Fischer, H., Meier, J., Brogli, M., Svendsen, L., 1987. Characterization of the protein C activator Protac from the venom of the southern copperhead (Agkistrodon contortrix) snake. Toxicon 25, 239-252.
93. Stocker, K., 1990. Snake venom proteins affecting hemostasis and fibrinolysis, in: Stocker, K. (Ed.), Medical Use of Snake Venom Proteins. CRC Press, Inc., Boca Raton, pp. 97-160.
94. Suzuki, K., Nishioka, J., 1988. Plasma protein S activity measured using Protac, a snake venom derived activator of protein C. Thromb. Res. 49, 241-251.
95. Takeya, H., Nishida, S., Miyata, T., Kawada, S., Saisaka, Y., Morita, T., Iwanaga, S., 1992. Coagulation factor X activating enzyme from Russell's viper venom (RVV-X). A novel metalloproteinase with disintegrin (platelet aggregation inhibitor)-like and C-type lectin-like domains. J. Biol. Chem. 267, 14109-14117.
96. Tans, G., Rosing, J., 2001 Snake venom activators of factor X: An overview, in: Bon, C., Kini, M., Markland, F.S., Marsh, N.A., Rosing, J. (Eds.), International Conference on Exogenous Factors Affecting Thrombosis and Haemostasis. Haemostasis 31, S. Karger Medical and Scientific Publishers, pp. 225-233.
97. Thiagarajan, P., Pengo, V., Shapiro, S.S., 1986. The use of dilute Russell viper venom time for the diagnosis of lupus coagulants. Blood 68, 869-874.
98. Tokunaga, F., Nagasawa, K., Tamura, S., Miyata, T., Iwanaga, S., Kisiel, W., 1988. The factor Vactivating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. J. Biol. Chem. 263, 17471-17481.
99. Torbet, J., 1987. Fibrin assembly after fibrinopeptide A release in model systems and human plasma studied with magnetic birefringence. Biochem. J. 15, 633-637.
100. Toulon, P., Halbmeyer, W.M., Hafner, G., Schmitt, Y., Randgard, B., Odpadlik, M., van den Eynden, C., Wagner, C., 2000. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation. Blood Coagul. Fibrinolysis 11, 447-454.
101. Triplett, D.A., Stocker, K., Unger, G.A., Barna, L.K., 1993. The textarin/ecarin ratio: A confirmatory test for lupus anticoagulants. Thromb. Haemost. 70, 925-931.
102. Van Cott, E.M., Smith, E.Y., Galanakis, D.K., 2002. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am. J. Clin. Path. 118, 263-268.
103. Weinger, R.S., Rudy, C., Moake, J.L., Olson, J.D., Cimo, P.L., 1980. Prothrombin Houston: A dysprothrombin identifiable by crossed immunoelectrofocussing and abnormal Echis carinatus venom activation. Blood 55, 811-815.
104. Wijeyewickrema, L., Berndt, M.C., Andrews, R.K., 2005. Snake venom probes of platelet adhesion receptors and their ligands. Toxicon 45, 1051-61.
105. Williams, S.B., McKeown, L.P., Krutzsch, H., Hansmann, K., Gralnick, H.R., 1994. Purification and characterization of human platelet von Willebrand factor. Br. J. Haematol. 88, 582-591.
106. Wilmer, M., Stocker, C., Bühler, B., Conell, B., Calatzis, A., 2004. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay. Am. J. Clin. Pathol. 122, 836-842.
107. Yamada, D., Morita, T., 1997. Purification and characterization of a Ca2+-dependent prothrombin activator, multactivase, from the venom of Echis multisquamatus. J. Biochem. 122, 991-997.
108. Yamada, D., Morita, T., 1999. CA-1 method, a novel assay for quantification of normal prothrombin using a Ca2+-dependent prothrombin activator, carinactivase-1. Thromb. Res. 94, 221-226.
109. Yamada, D., Sekiya, F., Morita, T., 1996. Isolation and characterization of carinactivase, a novel prothrombin activator in Echis carinatus venom with a unique catalytic mechanism. J. Biol. Chem. 271, 5200-5207.